Vertex Pharmaceuticals

The $110B market cap company that functionally cured cystic fibrosis with Trikafta, helping 90% of patients with $9B in revenue, making it 40% cheaper than the average genetic disease therapy per patient. Vertex is now applying the same precision medicine approach to pain, diabetes, and kidney disease, targeting a $20B addressable market.